Risk Factors Update Summary
- Net losses increased from $106.5 million to $123 million, with accumulated deficit rising from $292.8 million to $416.3 million.
- Expenses may substantially increase as clinical trials progress, particularly for mecbotamab vedotin, ozuriftamab vedotin, evalstotug, and BA3182.
- Cash and cash equivalents decreased significantly from approximately $215.5 million to $111.5 million.
- Employee count decreased from 66 to 65, while dedicated independent contractors increased from 19 to 21.
- Directors from underrepresented communities mandated based on board size, challenging enforceability.
- Potential impact on clinical trial operations due to global animal shortage for drug development.
- Increased complexity and potential legal risks due to state data privacy laws.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1826892&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.